×
About 4,293 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  1,406 results

The analysis of prognostic factors of primary small intestinal gastrointestinal stromal...
https://doi.org/10.1097/MD.0000000000029487
Medicine Qu H, Xu Z et. al.

Jun 28th, 2022 - We aim to assess factors that affect overall survival in patients with primary small intestinal gastrointestinal stromal tumors (GISTs) who had undergone R0 resection. A retrospective analysis reviewed the data of 82 consecutive confirmed GIST pat...

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
https://clinicaltrials.gov/ct2/show/NCT04557969

Jun 24th, 2022 - Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal soft tissue sarcoma, but remain a rare disease entity. Most GISTs are characterized by KIT or PDGFRA mutations, making them susceptible to tyrosine kinase inh...

Next questions for the medical treatment of gastrointestinal stromal tumor.
https://doi.org/10.1097/CCO.0000000000000845
Current Opinion in Oncology; Italiano A

Jun 23rd, 2022 - Since its approval in 2002, imatinib remains the standard first-line treatment for patients with advanced gastrointestinal stromal tumors (GISTs). Overall, all the drugs approved for patients who have developed secondary resistance to imatinib are...

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02508532

Jun 21st, 2022 - This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult...

Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors: What Surgeons S...
https://doi.org/10.1016/j.soc.2022.03.002
Surgical Oncology Clinics of North America; Callegaro D, Roland CL et. al.

Jun 18th, 2022 - In the past few years, the sarcoma community has successfully completed several trials in patients with soft tissue sarcoma (STS) or gastrointestinal stromal tumor (GIST). The current review summarizes recently reported relevant trials or trial up...

see more →

Guidelines  4 results

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 26th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 30th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treat...
https://doi.org/10.1093/annonc/mds252
Annals of Oncology : Official Journal of the European Soc...

Nov 20th, 2012 - Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012| ,|therapeutic use,diagnosis,genetics,therapy,diagnosis,genetics,therapy,therapeutic use,therapeutic use,

Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment...
https://doi.org/10.1093/annonc/mdn080
Annals of Oncology : Official Journal of the European Soc... Casali PG, Jost L et. al.

May 9th, 2008 - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Casali PG,Jost L,Reichardt P,Schlemmer M,Blay JY,|diagnosis,epidemiology,pathology,therapy,

see more →

Drugs  1 results see all →

Clinicaltrials.gov  120 results

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
https://clinicaltrials.gov/ct2/show/NCT04557969

Jun 24th, 2022 - Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal soft tissue sarcoma, but remain a rare disease entity. Most GISTs are characterized by KIT or PDGFRA mutations, making them susceptible to tyrosine kinase inh...

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02508532

Jun 21st, 2022 - This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult...

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
https://clinicaltrials.gov/ct2/show/NCT02461849

Jun 15th, 2022 - KIT is a receptor tyrosine kinase that binds to stem-cell factor (SCF), activating a series of downstream effector pathways. KIT is an established therapeutic target in cancer with activating mutations of KIT, such as gastrointestinal stromal tumo...

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, An...
https://clinicaltrials.gov/ct2/show/NCT01416714

Jun 8th, 2022 - The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer ...

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
https://clinicaltrials.gov/ct2/show/NCT05408897

Jun 7th, 2022 - Assessing MRD (Minimal Residual Disease) and predicting the recurrence risk of tumor patients based on liquid biopsy ctDNA have been exploratory studies and applications in many cancer types, but for stromal-derived tumors such as gastrointestinal...

see more →

News  185 results

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Ripretinib Safer Than Sunitinib for Advanced GIST, but Fails to Improve PFS
https://www.medscape.com/viewarticle/967401

Jan 27th, 2022 - The multitargeted tyrosine kinase inhibitor ripretinib (Qinlock) showed comparable efficacy and less toxicity compared with sunitinib (Sutent), but failed to improve progression-free survival (PFS), a phase 3 trial of adults with advanced gastroin...

Gastrointestinal Stromal Tumors Clinical Practice Guidelines (ESMO/EURACAN/GENTURIS, 2021)
https://www.medscape.com/viewarticle/963975

Dec 3rd, 2021 - Guidelines for the diagnosis, treatment, and follow-up of gastrointestinal stromal tumors (GISTs) were published in September 2021 by the European Society for Medical Oncology (ESMO), European Reference Network for Rare Adult Solid Cancers (EURACA...

PSA Paradox; Good News for Advanced Breast Cancer; AI Not Ready for Skin Cancer Dx
https://www.medpagetoday.com/hematologyoncology/prostatecancer/95577

Nov 10th, 2021 - The paradox of the PSA test. (MIT Press) Helping patients with cancer feel more like someone who matters and less like a number. (Time) Deciphera Pharmaceuticals announced that the switch-control tyrosine kinase inhibitor ripretinib (Qinlock) fail...

Promising TH-302 Results Accelerate Sarcoma Study
https://www.onclive.com/view/promising-th-302-results-accelerate-sarcoma-study

Oct 6th, 2021 - William D. Tap, MD Section Chief, Sarcoma Oncology Melanoma and Sarcoma Services Memorial Sloan-Kettering Cancer Center New York, NY The list of agents currently available to treat soft-tissue sarcoma is rather sh...

see more →

Patient Education  1 results see all →